Indivior Pharmaceuticals (INDV) Income from Continuing Operations (2024 - 2026)
Indivior Pharmaceuticals (INDV) posted quarterly Income from Continuing Operations of 89000000.0 for Q1 2026, up 85.42% year-over-year from 48000000.0 in Q1 2025, and down 12.75% quarter-over-quarter from 102000000.0 in Q4 2025.
Indivior Pharmaceuticals (INDV) Income from Continuing Operations (2024 - 2026) Analysis & Trends
Indivior Pharmaceuticals' Income from Continuing Operations history runs 3 years deep, the most recent figure standing at 89000000.0 for Q1 2026.
- In Q1 2026, Income from Continuing Operations rose 85.42% year-over-year to 89000000.0; the TTM figure through Mar 2026 stood at 251000000.0 (up 3685.71% YoY), while the FY2025 annual figure was 210000000.0, up 2900.0% from the prior year.
- Income from Continuing Operations for Q1 2026 stood at 89000000.0, down from 102000000.0 in the prior quarter.
- The five-year high for Income from Continuing Operations was 102000000.0 in Q4 2025, with the low at 98000000.0 in Q2 2024.
- The 3-year median for Income from Continuing Operations is 42000000.0 (2025), against an average of 34000000.0.
- Peak annual rise in Income from Continuing Operations reached 385.71% in 2025, while the deepest fall reached 22.58% in 2025.
- Indivior Pharmaceuticals' Income from Continuing Operations stood at 21000000.0 in 2024, then surged by 385.71% to 102000000.0 in 2025, then decreased by 12.75% to 89000000.0 in 2026.
- Business Quant data shows INDV's Income from Continuing Operations at 89000000.0 in Q1 2026, 102000000.0 in Q4 2025, and 42000000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 44.07 Bn | 43.10 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.41 Bn | 39.75 Bn | 2.15 Bn | -576.00 Mn |
| 3 | Zoetis | 31.83 Bn | 30.15 Bn | 1.05 Bn | 866.00 Mn |
| 4 | Takeda Pharmaceutical | 28.77 Bn | 22.97 Bn | 5.10 Bn | 1.33 Bn |
| 5 | United Therapeutics | 22.27 Bn | 19.61 Bn | 683.80 Mn | 333.00 Mn |
| 6 | Viatris | 18.76 Bn | 17.87 Bn | 1.46 Bn | -118.80 Mn |
| 7 | Neurocrine Biosciences | 15.65 Bn | 15.26 Bn | 935.80 Mn | 144.40 Mn |
| 8 | Elanco Animal Health | 11.93 Bn | 11.40 Bn | 798.00 Mn | 54.00 Mn |
| 9 | Dr Reddys Laboratories | 10.16 Bn | 10.00 Bn | - | - |
| 10 | Indivior Pharmaceuticals | 4.58 Bn | 4.36 Bn | 294.00 Mn | 122.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 122.00 Mn |
| Mar 31, 2026 | 89.00 Mn |
| Dec 31, 2025 | 102.00 Mn |
| Sep 30, 2025 | 42.00 Mn |
| Jun 30, 2025 | 18.00 Mn |
| Mar 31, 2025 | 48.00 Mn |
| Dec 31, 2024 | 21.00 Mn |
| Sep 30, 2024 | 22.00 Mn |
| Jun 30, 2024 | -98.00 Mn |
| Mar 31, 2024 | 62.00 Mn |